Comparative Pharmacology
Head-to-head clinical analysis: NATURAL ESTROGENIC SUBSTANCE ESTRONE versus PMB 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NATURAL ESTROGENIC SUBSTANCE ESTRONE versus PMB 400.
NATURAL ESTROGENIC SUBSTANCE-ESTRONE vs PMB 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrone binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent estrogenic effects on target tissues.
PMB 400 is a combination of progesterone and micronized estradiol; progesterone suppresses gonadotropin secretion and transforms proliferative endometrium into secretory endometrium, while estradiol replaces endogenous estrogen production and promotes growth of reproductive tissues.
0.1 to 0.5 mg intramuscularly 2 to 3 times per week for estrogen replacement therapy
1 tablet (400 mg Pregabalin, 400 mg Mirogabalin, 100 mg Benfotiamine) orally once daily.
None Documented
None Documented
Terminal half-life: 24-48 hours (prolonged due to enterohepatic recirculation and tissue distribution).
Terminal elimination half-life is 12-16 hours in adults with normal renal function; may be prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~50% (as glucuronide and sulfate conjugates), Biliary/Fecal: ~50% (enterohepatic recirculation).
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism via CYP3A4 produces inactive metabolites, with biliary/fecal excretion of metabolites (20-30%) and parent compound (<5%).
Category C
Category C
Estrogen
Estrogen/Progestin Combination